A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Six-Week Study Of The Efficacy And Safety Of Tofimilast Dry Powder For Inhalation In Adults With Persistent Asthma

Purpose:

This is an initial proof of concept, phase to study to assess the safety and efficacy tofimilast for the chronic maintenance treatment of adults with persistent asthma

Criteria:

Inclusion Criteria: - Mild to moderate persistent asthma (NAEPP/GINA Step 2-3) - Reversibility to albuterol at least 12% and 200 mL Exclusion Criteria: - Any significant co-morbid disease, particularly cardiovascular - Use of any maintenance therapy except short acting bronchodilators - Smoking history > or = 10 years

NCT ID:

NCT00150397

Primary Contact:

Study Director
Pfizer CT.gov Call Center
Pfizer

Backup Contact:

N/A

Location Contact:

DeLand, Florida 32720
United States



There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: November 18, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.